Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My Custom Filters

Results by year

Table representation of search results timeline featuring number of search results per year.

Year Number of Results
2015 1
2017 1
2018 3
2021 1
2022 5
2023 1
2024 6

Publication date

Text availability

Article attribute

Article type

Additional filters

Article Language

Species

Sex

Age

Other

Search Results

17 results

Results by year

Filters applied: . Clear all
Page 1
Transcriptional and functional profiling identifies inflammation and endothelial-to-mesenchymal transition as potential drivers for phenotypic heterogeneity within a cohort of endothelial colony forming cells.
Laan SNJ, de Boer S, Dirven RJ, van Moort I, Kuipers TB, Mei H, Bierings R, Eikenboom J; SYMPHONY consortium. Laan SNJ, et al. J Thromb Haemost. 2024 Jul;22(7):2027-2038. doi: 10.1016/j.jtha.2024.03.018. Epub 2024 Apr 2. J Thromb Haemost. 2024. PMID: 38574861 Free article.
Desmopressin testing in von Willebrand disease: Lowering the burden.
Heijdra JM, Atiq F, Al Arashi W, Kieboom Q, Wuijster E, Meijer K, Kruip MJHA, Leebeek FWG, Cnossen MH; OPTI‐CLOT Study Group. Heijdra JM, et al. Among authors: al arashi w. Res Pract Thromb Haemost. 2022 Sep 26;6(6):e12784. doi: 10.1002/rth2.12784. eCollection 2022 Aug. Res Pract Thromb Haemost. 2022. PMID: 36186107 Free PMC article.
Is pharmacokinetic-guided dosing of desmopressin and von Willebrand factor-containing concentrates in individuals with von Willebrand disease or low von Willebrand factor reliable and feasible? A protocol for a multicentre, non-randomised, open label cohort trial, the OPTI-CLOT: to WiN study.
Heijdra JM, Al Arashi W, de Jager NCB, Cloesmeijer ME, Bukkems LH, Zwaan CM, Leebeek FWG, Mathôt RAA, Cnossen MH; OPTI-CLOT Study Group. Heijdra JM, et al. Among authors: al arashi w. BMJ Open. 2022 Feb 15;12(2):e049493. doi: 10.1136/bmjopen-2021-049493. BMJ Open. 2022. PMID: 35168962 Free PMC article.
Functional characterization of a nanobody-based glycoprotein VI-specific platelet agonist.
Zivkovic M, Pols-van Veen E, van der Vegte V, Sebastian SAE, de Moor AS, Korporaal SJA, Schutgens REG, Urbanus RT; Thrombocytopathy in the Netherlands (TiN) study group; SYMPHONY consortium. Zivkovic M, et al. Res Pract Thromb Haemost. 2024 Oct 3;8(7):102582. doi: 10.1016/j.rpth.2024.102582. eCollection 2024 Oct. Res Pract Thromb Haemost. 2024. PMID: 39512585 Free PMC article.
17 results